Joe Schwartz

Where do you see the organic demand coming from most now and going forward? Community or academic practices

I was wondering if you have any plans to develop other DPP1 inhibitors within respiratory disease in order to expand your franchise further?

how frictionless has the launch been to date in your view based on the amount of documentation physicians have had to provide to payers?

I wanted to ask if you could expand on the qualitative statements you've made about the BiRCh trial showing positive signs before you unblind it

how do you feel about the availability of adequate FDA staff remaining in place to review brensocatib on time?

What other factors are in your control and are you leveraging to ensure a strong launch for brenso in bronchiectasis?